PMID- 32973649
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain 
      Tumor-Related Epilepsy: A Retrospective Multicenter Study.
PG  - 813
LID - 10.3389/fneur.2020.00813 [doi]
LID - 813
AB  - Background: Epilepsy is a common symptom of brain tumors and is often 
      pharmacoresistent. Among new antiseizure medications (ASMs) Brivaracetam (BRV) 
      has been approved as adjunctive treatment for focal seizures and it was tested in 
      non-oncological patient populations. This is the first study that retrospectively 
      explored efficacy and tolerability of BRV as add-on therapy in brain 
      tumor-related epilepsy (BTRE) patients. Materials and Methods: We reviewed the 
      medical records of 33 BTRE patients from six Italian epilepsy centers; charts 
      included tumor history, diagnosis of BTRE, BRV added as first or second add-on 
      for uncontrolled seizures and/or adverse events (AEs) of the previous ASMs, at 
      least 1-month follow-up, seizure frequency, and AEs assessment. Results: 
      Thirty-three patients (19 males, mean age: 57.6 years; 14 females, mean age: 42.4 
      years): 11 low grade gliomas, five high grade gliomas, six meningiomas, 10 
      glioblastomas, one primary cerebral lymphoma. Fourteen patients had focal aware 
      seizures, nine focal unaware, seven focal to bilateral tonic-clonic seizures, 
      three patients presented more than one seizure type: focal unaware with focal to 
      bilateral tonic clonic seizures (two patients) and focal aware and unaware 
      seizures (one patient). Mean seizure frequency in the month preceding BRV 
      introduction: 7.0; at last follow-up: 2.0 (p = 0.001). Seven patients (21.2%) 
      reported AEs (anxiety, agitation, fatigue, vertigo) and three of them (9.0%) 
      required drug withdrawal due to psychiatric adverse events (PAEs). Three other 
      patients withdrew BRV: one for scarce compliance (3.0%), two for uncontrolled 
      seizures (6.0%). Conclusion: Our results showed that BRV could be a new 
      therapeutic option effective in reducing seizures in BTRE patients, taking into 
      account the incidence of PAEs in this particular population. Future and larger 
      prospective studies are needed.
CI  - Copyright (c) 2020 Maschio, Maialetti, Mocellini, Domina, Pauletto, Costa, Mascia, 
      Romoli and Giannarelli.
FAU - Maschio, Marta
AU  - Maschio M
AD  - Center for Tumor-Related Epilepsy, UOSD Neurology, Regina Elena National Cancer 
      Institute IRCCS IFO, Rome, Italy.
FAU - Maialetti, Andrea
AU  - Maialetti A
AD  - Center for Tumor-Related Epilepsy, UOSD Neurology, Regina Elena National Cancer 
      Institute IRCCS IFO, Rome, Italy.
FAU - Mocellini, Cristina
AU  - Mocellini C
AD  - UO Neurology ASO S. Croce e Carle, Cuneo, Italy.
FAU - Domina, Elisabetta
AU  - Domina E
AD  - U.C. Neurology, Ospedale Maggiore di Lodi ASST, Lodi, Italy.
FAU - Pauletto, Giada
AU  - Pauletto G
AD  - Neurology Unit, Azienda Sanitaria Universitaria, ASUFC, Udine, Italy.
FAU - Costa, Cinzia
AU  - Costa C
AD  - Clinic of Neurology, Ospedale SM Misericordia, Universita degli Studi di Perugia, 
      Perugia, Italy.
FAU - Mascia, Addolorata
AU  - Mascia A
AD  - Center for Epilepsy Surgery, IRCCS Neuromed, Pozzilli, Italy.
FAU - Romoli, Michele
AU  - Romoli M
AD  - Clinic of Neurology, Ospedale SM Misericordia, Universita degli Studi di Perugia, 
      Perugia, Italy.
FAU - Giannarelli, Diana
AU  - Giannarelli D
AD  - Biostatistic Unit, Regina Elena National Cancer Institute IRCCS IFO, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7466736
OTO - NOTNLM
OT  - adverse events
OT  - antiseizure medication
OT  - brain tumor-related epilepsy
OT  - brivaracetam
OT  - glioma
OT  - responder rate
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
PMCR- 2020/08/19
CRDT- 2020/09/25 06:01
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/09/25 06:01 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
PHST- 2020/08/19 00:00 [pmc-release]
AID - 10.3389/fneur.2020.00813 [doi]
PST - epublish
SO  - Front Neurol. 2020 Aug 19;11:813. doi: 10.3389/fneur.2020.00813. eCollection 
      2020.